Search

everythinglearnresearchcommunity

for

Search:↓

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

New medications could improve treatment for severe alopecia areata in Australia.

Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.

Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.

Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

QLT0267 stops hair follicle cell growth and movement.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.

ALA-photodynamic therapy helps reduce acne by causing acne cell death and lowering certain skin protein levels.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

AS101 reduces hair loss from chemotherapy.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.

Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.